Joe Rogan TRT Public Transformation Timeline

What Joe Rogan Has Actually Said About TRT

Joe Rogan has been direct. He is not a reluctant discloser. Across dozens of JRE episodes recorded between 2013 and 2024, he has named his therapies, described his dosing philosophy, and credited TRT with changing how he feels and looks in his fifties compared to his forties.

His clearest early statement came during a 2013 JRE episode in which he described beginning testosterone therapy with physician supervision after bloodwork confirmed low-normal testosterone. He has since referenced TRT in episodes with guests including Dr. Mark Gordon, Peter Attia, Andrew Huberman, and Rhonda Patrick.

The Core Disclosure: TRT With Physician Oversight

Rogan has consistently described his TRT as medically supervised, not self-administered. He named Dr. Mark Gordon, a physician focused on hormone optimization and traumatic brain injury, as an early prescribing clinician. On JRE episode 524 (released 2014), Rogan stated he uses testosterone "prescribed by a doctor" and frames it as corrective rather than performance-enhancing in the athletic sense.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy defines symptomatic hypogonadism as total testosterone below 300 ng/dL on two morning measurements, combined with consistent symptoms such as fatigue, reduced libido, and loss of lean mass. [1] Rogan's described rationale, low energy and poor recovery from training despite a clean diet, fits this clinical picture, though his specific lab values have not been publicly disclosed.

NAD+ and Peptide Disclosures

Beyond testosterone, Rogan has publicly discussed NAD+ (nicotinamide adenine dinucleotide) IV infusions as a recovery and cognitive tool. He described multi-day NAD+ infusion protocols, typically 500 to 1,000 mg IV over several hours, as producing noticeable mental clarity and physical energy improvements.

He has also referenced BPC-157, a synthetic peptide derived from a body protection compound originally isolated from human gastric juice, for joint recovery. [2] BPC-157 is not FDA-approved for human use, a point Rogan has acknowledged on-air, and its evidence base currently rests primarily on rodent studies rather than controlled human trials.

Human growth hormone (HGH) has been mentioned episodically, though Rogan has described cycling off it and has been less consistent in claiming current use compared to TRT.

The Transformation Timeline: 2013 to 2024

Rogan turned 46 in 2013. His physical appearance, training output, and self-reported wellbeing over the following decade tracked with what the clinical literature predicts from sustained TRT in a physically active, low-body-fat male.

2013 to 2016: Baseline Correction Phase

Rogan was already lean and trained at 46. His publicly disclosed motivation for starting TRT was not dramatic weight loss but rather restoring energy and training recovery to levels he associated with his mid-thirties. This matches the clinical evidence: a 2010 meta-analysis of 29 randomized controlled trials published in the Journal of Clinical Endocrinology and Metabolism found that testosterone therapy in hypogonadal men produced statistically significant improvements in lean body mass, fat mass reduction, and self-reported energy within 3 to 6 months of initiation. [3]

Body composition changes in this phase are typically modest in already-lean men. The larger gains come in subjective energy, libido, and training recovery, which Rogan described consistently in JRE episodes from this period.

2016 to 2019: Sustained Optimization Phase

By his early fifties, Rogan's physique had visibly shifted toward greater muscle retention. This is consistent with TRT's known effects on muscle protein synthesis. A 2001 NEJM study by Bhasin et al. (N=61) demonstrated dose-dependent increases in fat-free mass with exogenous testosterone, with the 600 mg/week group gaining an average of 7.9 kg of fat-free mass over 20 weeks. [4] Rogan's described use is at therapeutic doses, not supraphysiologic, but the directional biology is the same.

He also began describing NAD+ infusions more frequently during this period, crediting them with accelerated recovery from injury and improved cognitive performance during long podcast recording sessions.

2019 to 2024: Public Consolidation and Expanded Protocol

After signing with Spotify in 2020, Rogan's public profile increased substantially. His physical appearance at ages 52 to 57 drew significant online commentary, with many observers noting muscle retention atypical for natural aging in the absence of resistance training optimization and hormonal support.

Rogan addressed this directly in multiple episodes. He has stated his protocol includes TRT, NAD+, and periodic peptide use, combined with Brazilian jiu-jitsu training four to five days per week and a meat-heavy carnivore-adjacent diet. Separating which intervention drives which outcome is clinically impossible without a controlled design. That is an important limitation.

Age-related testosterone decline averages 1 to 2 percent per year after age 30, according to data from the Massachusetts Male Aging Study. [5] A man who does not intervene hormonally can expect roughly 20 to 30 percent lower testosterone by his mid-fifties compared to his peak levels. TRT arrests that decline by exogenous replacement.

Clinical Context: What TRT Actually Does

TRT is not a cosmetic intervention. The Endocrine Society guideline characterizes it as a treatment for a defined medical condition with measurable endpoints. [1] Understanding Rogan's transformation requires understanding what the therapy does mechanistically.

Testosterone and Body Composition

Testosterone promotes skeletal muscle protein synthesis via androgen receptor activation in muscle tissue. It also reduces fat mass, particularly visceral fat, by inhibiting lipid uptake in adipocytes and increasing lipolysis. [6] A 2012 Cochrane systematic review (17 RCTs, N=1,084) found that testosterone therapy produced a mean reduction in fat mass of 1.6 kg and a mean increase in lean mass of 1.6 kg compared to placebo in middle-aged and older men. [7]

At 57, Rogan maintains a physique that would require substantial lean mass preservation. TRT is the most clinically documented tool for that goal in aging men.

Testosterone and Cognitive Function

Rogan frequently credits TRT with mental sharpness. The evidence here is more mixed than for body composition. A 2016 NEJM trial, the Testosterone Trials (TTrials, N=790), found modest improvement in sexual function and mood but did not show statistically significant cognitive improvement in the primary cognitive sub-trial. [8] Later analysis of the TTrials cognitive sub-study did show improvement in spatial memory but not in other domains. This is worth noting without overstating.

Testosterone and Cardiovascular Considerations

No discussion of TRT is complete without acknowledging cardiovascular risk. A 2023 randomized trial published in NEJM, TRAVERSE (N=5,204), found that testosterone replacement in middle-aged and older men with hypogonadism and pre-existing cardiovascular risk factors did not significantly increase major adverse cardiovascular events compared to placebo over approximately 33 months. [9] The trial was designed specifically to address prior observational safety concerns.

That does not make TRT risk-free. Hematocrit elevation, which increases thrombotic risk, requires monitoring. The Endocrine Society guideline recommends checking hematocrit at baseline, at 3 months, and then annually. [1]

NAD+ Infusions: The Evidence Behind Rogan's Second Pillar

NAD+ is a coenzyme central to mitochondrial energy production and DNA repair. Levels decline with age. Rogan has described IV NAD+ infusions as producing rapid improvements in energy and cognitive clarity.

What the Research Shows

Oral NAD+ precursors, specifically nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), have been studied in human trials. A 2018 Phase 1 study published in Nature Communications (N=12) confirmed that oral NR 1,000 mg/day safely increased blood NAD+ levels by approximately 2.7-fold compared to baseline. [10] IV NAD+ bypasses gut absorption and is expected to produce larger and faster NAD+ elevation, though head-to-head IV versus oral data in humans remain limited.

The FDA has not approved any NAD+ formulation for anti-aging indications. Its use is off-label, and the evidence for the specific outcomes Rogan describes, mental clarity and physical recovery, is preliminary rather than conclusive.

Protocol Details Rogan Has Disclosed

Rogan has described protocols of 500 to 1,000 mg IV NAD+ administered over 4 to 8 hours by a licensed clinician, often timed around periods of heavy travel or before major events. He has described the infusion experience as uncomfortable during administration but followed by a noticeable energy shift within 24 to 48 hours. These details are consistent with clinician reports in the NAD+ infusion literature, though that literature is largely case-based rather than trial-based.

BPC-157: What Rogan Takes for Joint Recovery

BPC-157 is a synthetic pentadecapeptide (15 amino acids) that has shown pro-anabolic and cytoprotective effects in rodent models of tendon, ligament, and gut injury. Rogan has described using it for BJJ-related joint wear, consistent with its primary studied application in soft tissue healing.

A 2018 review in the Journal of Physiology and Pharmacology summarized the preclinical evidence: BPC-157 accelerated tendon-to-bone healing in rat models, appeared to modulate nitric oxide signaling, and demonstrated gastroprotective effects. [11] No Phase 2 or Phase 3 human RCTs have been completed as of mid-2025. The FDA has not approved BPC-157 and the compound's regulatory status means it cannot legally be marketed as a drug in the US.

Rogan has acknowledged this regulatory status on-air. He frames his personal use as informed self-experimentation under clinical supervision, not a recommendation for listeners.

How to Evaluate Your Own TRT Candidacy

Rogan's case is clinically interesting precisely because he disclosed his labs, his symptoms, his clinician, and his rationale publicly over time. Most men considering TRT do not have that roadmap.

The Standard Diagnostic Pathway

The American Urological Association's 2018 Guideline on Testosterone Deficiency recommends the following diagnostic steps for men presenting with low-T symptoms. [12]

First, obtain two early-morning total testosterone measurements (before 10 a.m.) on separate days. Values below 300 ng/dL on both measurements, combined with consistent symptoms, meet the diagnostic threshold. Second, rule out secondary causes: pituitary adenoma, hemochromatosis, opioid use, and anabolic steroid use all suppress the HPG axis and require specific management. Third, assess fertility intent. Exogenous testosterone suppresses intratesticular testosterone and spermatogenesis. Men who want biological children should consider clomiphene citrate or human chorionic gonadotropin (hCG) protocols rather than or alongside direct testosterone administration.

Monitoring Once Therapy Starts

The Endocrine Society recommends reassessing total testosterone at 3 months after TRT initiation, targeting mid-normal range (typically 400 to 700 ng/dL on most assays, though some guidelines target higher). [1] Hematocrit above 54 percent requires dose reduction or temporary discontinuation. PSA should be checked at baseline and 3 months in men over 40.

Dr. Peter Attia, who has discussed TRT extensively on his own podcast and has appeared on JRE, has stated: "The goal of testosterone therapy is not to get your testosterone as high as possible. The goal is to restore a level that eliminates the symptoms of deficiency without creating new problems." This framing matches the Endocrine Society's guideline language precisely.

What Rogan's Public Disclosure Means for the TRT Conversation

Rogan reaches an estimated 11 million listeners per episode, according to Edison Research's Infinite Dial 2023 report. His open discussion of TRT has almost certainly increased the number of men who ask their primary care physicians about testosterone testing. Whether that is good or bad depends on the clinical execution that follows.

The Normalization Effect

Research from the CDC's National Health Interview Survey found that testosterone prescribing in US men rose approximately 300 percent between 2001 and 2011, then moderated following FDA safety labeling updates in 2015. [13] Podcast-driven celebrity disclosure is a plausible contributor to that trend, though attribution is observational.

Normalizing TRT has genuine public health upside: many men with symptomatic hypogonadism go undiagnosed for years, attributing their fatigue, depression, and body composition changes to unavoidable aging. Early identification and treatment can meaningfully improve quality of life.

The downside is off-label, non-supervised use. Men who self-administer testosterone without baseline labs, without monitoring hematocrit and PSA, and without understanding HPG axis suppression face real risks.

The Clinical Instruction That Matters

If Rogan's public discussion of TRT motivates you to consider therapy, the correct first step is a morning total testosterone draw, not a direct-to-pharmacy testosterone purchase. Diagnosis precedes treatment. A single lab result below 300 ng/dL is not sufficient. Two values on separate mornings, combined with clinical symptoms scored on a validated instrument such as the Androgen Deficiency in the Aging Male (ADAM) questionnaire, constitute an appropriate diagnostic basis. [12]